[1]
|
Wang, H. and Mao, X. (2020) Evaluation of the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer. Drug Design, Development and Therapy, 14, 2423-2433. https://doi.org/10.2147/DDDT.S253961
|
[2]
|
Akram, M., Iqbal, M., Daniyal, M. and Khan, A.U. (2017) Awareness and Current Knowledge of Breast Cancer. Biological Research, 50, Arti-cle No. 33. https://doi.org/10.1186/s40659-017-0140-9
|
[3]
|
毕钊, 王永胜. 乳腺癌新辅助治疗后局部区域处理降阶梯策略[J]. 山东第一医科大学(山东省医学科学院)学报, 2023, 44(4): 249-253.
|
[4]
|
Liu, Y.G., Wu, M.X., Tan, W.Y., et al. (2022) Efficacy Evaluation of Neoadjuvant Chemotherapy in Breast Cancer by MRI. Contrast Media & Mo-lecular Imaging, 2022, Article ID: 4542288. https://doi.org/10.1155/2022/4542288
|
[5]
|
毕钊, 王永胜. 乳腺癌新辅助治疗策略与手术时机[J]. 中国实用外科杂志, 2021, 41(11): 1220-1225.
|
[6]
|
艾宪程, 徐翔宇. HER-2阳性局部晚期乳腺癌新辅助靶向治疗的研究进展[J]. 当代医学, 2021, 27(23): 190-194.
|
[7]
|
Shien, T. and Iwata, H. (2020) Adjuvant and Neoadjuvant Therapy for Breast Cancer. Japanese Journal of Clinical Oncology, 50, 225-229. https://doi.org/10.1093/jjco/hyz213
|
[8]
|
Gallagher, K.K. and Ollila, D.W. (2019) Indications for Neoadjuvant Sys-temic Therapy for Breast Cancer. Advances in Surgery, 53, 271-292. https://doi.org/10.1016/j.yasu.2019.04.013
|
[9]
|
陈安莉, 沈浩元, 王舒. 三阴性乳腺癌新辅助治疗的临床研究进展[J]. 现代肿瘤医学, 2023, 31(3): 566-571.
|
[10]
|
Derakhshan, F. and Reis-Filho, J.S. (2022) Pathogenesis of Tri-ple-Negative Breast Cancer. Annual Review of Pathology, 17, 181-204. https://doi.org/10.1146/annurev-pathol-042420-093238
|
[11]
|
Burstein, H.J., Curigliano, G., Loibl, S., et al. (2019) Estimating the Benefits of Therapy for Early-Stage Breast Cancer: The St. Gallen International Consensus Guidelines for the Primary Therapy of Early Breast Cancer 2019. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 30, 1541-1557.
https://doi.org/10.1093/annonc/mdz235
|
[12]
|
Chaudhary, L.N., et al. (2018) Triple-Negative Breast Cancer: Who Should Receive Neoadjuvant Chemotherapy? Surgical Oncology Clinics of North America, 27, 141-153.
|
[13]
|
Moore-Smith, L., Forero-Torres, A. and Stringer-Reasor, E. (2018) Future Developments in Neoadjuvant Therapy for Triple-Negative Breast Cancer. The Surgical Clinics of North America, 98, 773-785.
https://doi.org/10.1016/j.suc.2018.04.004
|
[14]
|
黄美玲, 李南林. 三阴性乳腺癌新辅助化疗中铂类的地位[J]. 医学争鸣, 2019, 10(3): 15-17.
|
[15]
|
何李华, 朱秀之, 江一舟. 三阴性乳腺癌免疫治疗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 842-853.
|
[16]
|
Sher, N.M., et al. (2022) Effects of Lipid Based Multiple Micronutrients Sup-plement on the Birth Outcome of Underweight Pre-Eclamptic Women: A Randomized Clinical Trial. Pakistan Journal of Medical Sciences, 38, 219-226.
https://doi.org/10.12669/pjms.38.1.4396
|
[17]
|
Lin, Y.-Y., Gao, H.-F., Yang, X., et al. (2022) Neoadjuvant Therapy in Triple-Negative Breast Cancer: A Systematic Review and Network Meta-Analysis. Breast (Edinburgh, Scotland), 66, 126-135.
https://doi.org/10.1016/j.breast.2022.08.006
|
[18]
|
Obidiro, O., Battogtokh, G. and Akala, E.O. (2023) Triple Nega-tive Breast Cancer Treatment Options and Limitations: Future Outlook. Pharmaceutics, 15, Article No. 1796. https://doi.org/10.3390/pharmaceutics15071796
|
[19]
|
张磊. 三阴性乳腺癌新辅助化疗研究进展[J]. 中国处方药, 2021, 19(9): 21-22.
|
[20]
|
何建林, 梅振宇, 盛勇, 等. 三阴性乳腺癌新辅助治疗研究进展[J]. 中国肿瘤外科杂志, 2018, 10(5): 330-332.
|
[21]
|
张亚楠, 宋晓宇, 汪胤, 等. 乳腺癌新辅助治疗研究进展[J]. 癌症进展, 2022, 20(22): 2284-2288.
|